Drugs Made In America Acquisition net income falls 24.55% to $1.73 million in Q2 FY26
DMAA•Quarterly net income declines as trust income falls
Drugs Made In America Acquisition posted net income of $1.73 million for the quarter ended June 30, 2026, down 24.55% year over year.
- Interest income from the trust account fell 23.00% to $1.86 million.
- General and administrative costs rose 3.80% to $136,934.
- Shareholder redemptions withdrew $99.31 million from the trust account; BV Advisory Partners deposited $600,000 for extensions through June 30.
Merger agreement with Power Analytics Global Corporation
The company signed a definitive merger agreement with Power Analytics Global Corporation on April 29, 2026. The deal targets a Nasdaq listing post-close.
